Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Clemons

Showing results (151-160 of 185) with videos related to

Pageof 19
Sort By:
Current Oncology (Toronto, Ont.)|August 13, 2009
The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancerS Dent, Sh Verma, J Latreille, et al.
Current Oncology (Toronto, Ont.)|August 17, 2018
Optimizing vascular access for patients receiving intravenous systemic therapy for early-stage breast cancer-a survey of oncology nurses and physiciansN LeVasseur, C Stober, K Daigle, et al.
Journal of Molecular Biology|July 17, 2001
Crystal structure of the 30 S ribosomal subunit from Thermus thermophilus: purification, crystallization and structure determinationW M Clemons, D E Brodersen, J P McCutcheon, et al.
Cell Reports|August 16, 2016
A Link between Integral Membrane Protein Expression and Simulated Integration EfficiencyStephen S Marshall, Michiel J M Niesen, Axel Müller, et al.
Current Oncology (Toronto, Ont.)|October 29, 2009
The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancersJ Lemieux, M Clemons, L Provencher, et al.
Current Oncology (Toronto, Ont.)|July 7, 2017
Physician "out of office" alert: does it work?M Clemons, A A Joy, J Hilton, et al.
Breast Cancer Research and Treatment|September 5, 2009
A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancerO C Freedman, E Amir, W Hanna, et al.
Current Oncology (Toronto, Ont.)|August 11, 2010
Optimizing the management of HER2-positive early breast cancer: the clinical realitySu Verma, S Lavasani, J Mackey, et al.
ACS Chemical Biology|March 17, 2026
Structures of Bacterial and Human Phosphoglycosyltransferases Bound to a Common Inhibitor Inform Selective TherapeuticsBeebee Yusrah Kaudeer, Jacob M Kirsh, Katsuhiko Mitachi, et al.
Biorxiv : the Preprint Server for Biology|December 25, 2025
Structures of bacterial and human phosphoglycosyltransferases bound to a common inhibitor inform selective therapeuticsBeebee Yusrah Kaudeer, Jacob M Kirsh, Katsuhiko Mitachi, et al.
Pageof 19

Showing results (151-160 of 185) with videos related to

Sort By:
Pageof 19
Current Oncology (Toronto, Ont.)|August 13, 2009
The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancerS Dent, Sh Verma, J Latreille, et al.
Current Oncology (Toronto, Ont.)|August 17, 2018
Optimizing vascular access for patients receiving intravenous systemic therapy for early-stage breast cancer-a survey of oncology nurses and physiciansN LeVasseur, C Stober, K Daigle, et al.
Journal of Molecular Biology|July 17, 2001
Crystal structure of the 30 S ribosomal subunit from Thermus thermophilus: purification, crystallization and structure determinationW M Clemons, D E Brodersen, J P McCutcheon, et al.
Cell Reports|August 16, 2016
A Link between Integral Membrane Protein Expression and Simulated Integration EfficiencyStephen S Marshall, Michiel J M Niesen, Axel Müller, et al.
Current Oncology (Toronto, Ont.)|October 29, 2009
The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancersJ Lemieux, M Clemons, L Provencher, et al.
Current Oncology (Toronto, Ont.)|July 7, 2017
Physician "out of office" alert: does it work?M Clemons, A A Joy, J Hilton, et al.
Breast Cancer Research and Treatment|September 5, 2009
A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancerO C Freedman, E Amir, W Hanna, et al.
Current Oncology (Toronto, Ont.)|August 11, 2010
Optimizing the management of HER2-positive early breast cancer: the clinical realitySu Verma, S Lavasani, J Mackey, et al.
ACS Chemical Biology|March 17, 2026
Structures of Bacterial and Human Phosphoglycosyltransferases Bound to a Common Inhibitor Inform Selective TherapeuticsBeebee Yusrah Kaudeer, Jacob M Kirsh, Katsuhiko Mitachi, et al.
Biorxiv : the Preprint Server for Biology|December 25, 2025
Structures of bacterial and human phosphoglycosyltransferases bound to a common inhibitor inform selective therapeuticsBeebee Yusrah Kaudeer, Jacob M Kirsh, Katsuhiko Mitachi, et al.
Pageof 19